6533b821fe1ef96bd127b8f6
RESEARCH PRODUCT
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma
Giuseppe CabibboSalvatore PettaMarco Barbã RaGabriele MissaleRoberto VirdoneEugenio CaturelliFabio PiscagliaFilomena MoriscoAntonio ColecchiaFabio FarinatiEdoardo GianniniFranco TrevisaniAntonio Craxã¬Massimo ColomboCalogero Cammã Laura BucciMarco ZoliFrancesca GarutiBarbara LenziMaurizio BiselliPaolo CaraceniAlessandro CucchettiAnnagiulia GramenziAlessandro GranitoDonatella MagalottiCarla SerraGiulia NegriniLucia NapoliVeronica SalvatoreFrancesca BeneventoLuisa Benvegnã¹Alessia GazzolaFrancesca MurerCaterina PozzanVeronica VaninAlessandro MoscatelliGaia PellegattaAntonino PicciottoVincenzo SavarinoFrancesca CiccaresePaolo Del PoggioStefano OlmiNicoletta De MatthaeisMariella Di Marco Claudia BalsamoElena VavassoriPaola RoselliSerena Dell’isolaAnna Maria IalungoElena RastrelliSimona AttardoMargherita RossiAndrea CostantinoAndrea AffrontiMarco AffrontiMarta MascariMartina FelderAndrea MegaAntonio GasbarriniMaurizio PompiliEmanuele RinninellaRodolfo SaccoValeria MismasFrancesco Giuseppe FoschiAnna Chiara Dall’aglioValentina FelettiArianna LanziFederica Mirici CappaElga NeriGiuseppe Francesco StefaniniStefano TamberiAndrea OlivaniElisabetta BiasiniGerardo NardoneMaria GuarinoGialuca Svegliati-baroniAlessio OrtolaniAlberto MasottoFabiana MarchettiMatteo ValerioFabio MarraSami AburasAndrea L InghilesiAlberta CappelliRita GolfieriMaria Cristina MosconiMatteo RenzulliPiero CoccoliMarco Sanduzzi ZamparelliLuisa Benvegnu'subject
Oncologymedicine.medical_specialtyCarcinoma HepatocellularrecurrenceHepatitis C virusmedicine.medical_treatmentmedicine.disease_causesurvivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyhepatocellular carcinoma; prognosis; recurrences; survivalHumansSurvival analysisHepatologyrecurrencesbusiness.industryLiver Neoplasmshepatocellular carcinomaHepatologymedicine.diseaseHepatitis Chepatocellular carcinoma; prognosis; recurrences; survival; Hepatology030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinoma030211 gastroenterology & hepatologyprognosisNeoplasm Recurrence LocalbusinessAdjuvantprognosidescription
Background & Aims: Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis were to estimate the recurrence and survival probabilities of HCV-related early HCC following complete response after potentially curative treatment and to identify predictors of recurrence and survival. Methods: Studies reporting time-dependent outcomes (HCC recurrence or death) after potentially curative treatment of HCV-related early HCC were identified in MEDLINE through May 2016. Data on patient populations and outcomes were extracted from each study by three independent observers and combined using a distribution-free summary survival curve. Primary outcomes were actuarial probabilities of recurrence and survival. Results: Eleven studies met the inclusion criteria. Pooled estimates of actuarial recurrence rates were 7.4% at 6 months and 47.0% at 2 years. Pooled estimates of actuarial survival rates were 79.8% at 3 years and 58.6% at 5 years. Heterogeneity among studies was highly significant for all outcomes. By univariate meta-regression analyses, lower serum albumin, randomized controlled trial study design and follow-up were independently associated with higher recurrence risk, whereas tumour size and alpha-foetoprotein levels were associated with higher mortality. Conclusions: This meta-analysis showed that recurrence risk and survival are extremely variable in patients with successfully treated HCV-related HCC, providing a useful benchmark for indirect comparisons of the benefits of DAAs and for a correct design of randomized controlled trials in the adjuvant setting.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |